[3] King produced a wide range of pharmaceuticals, including Altace for heart attack prevention, Levoxyl for hypothyroidism, Sonata, a sleeping aid, and Skelaxin, a muscle relaxant.

King Pharmaceuticals operated manufacturing facilities in Bristol, Tennessee; Rochester, Michigan; St. Louis, Missouri; St. Petersburg, Florida; and Middleton, Wisconsin.

[7] By December 1998 King had placed its sterile products business into a subsidiary it named Parkedale Pharmaceuticals.

[8] King Pharmaceuticals obtained about twenty smaller branded drugs from the start up of the company until it went public in June 1998.

Using profits from Altace, King continued to add product lines, the most significant purchases being Levoxyl, Thrombin, and Cytomel in 2000.

Then in 2004, Jeff Gregory stepped down as well after the SEC began investigations into King's Medicaid billing practices.

[16] Investors, most notably Carl Icahn, were critical of the merger, saying that Mylan was overpaying for King.

From the acquisition, King gained the patents on the pain management drugs, Flector and Embeda.